Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 6/20 | 0.49 |
| ▸ | INSR | P06213 | 4/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.46 |
| ▸ | MET | P08581 | 3/20 | 0.45 |
| ▸ | EGFR | P00533 | 4/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3449451 | 0.86 | AXL (0.57) | AXLALKEGFRAURKAMAPK1 | |
| SCHEMBL3449764 | 0.83 | MAPK1 (0.51) | AXLEGFRMAPK1 | |
| SCHEMBL3452720 | 0.83 | MAPK1 (0.51) | AXLEGFRMAPK1 | |
| SCHEMBL3450023 | 0.82 | MAPK1 (0.50) | AXLEGFRMAPK1 | |
| SCHEMBL3449638 | 0.82 | MAPK1 (0.50) | AXLEGFRMAPK1 | |
| SCHEMBL3451168 | 0.82 | MAPK1 (0.44) | AXLEGFRMAPK1 | |
| SCHEMBL3450656 | 0.81 | MAPK1 (0.49) | AXLEGFRMAPK1 | |
| SCHEMBL3450848 | 0.80 | MET (0.44) | AXLINSRALKMETEGFR | |
| SCHEMBL13310378 | 0.80 | BRD4 (0.52) | AXLEGFRCDK4MAPK1 | |
| SCHEMBL3344180 | 0.80 | NPC1 (0.53) | EGFRAURKAMAPK1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | AXL 2812/4885INSR 3066/4885ALK 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.